US20220362322A1 - Composition for inhibiting tumor proliferation comprising salvia plebeia extract as effective component - Google Patents
Composition for inhibiting tumor proliferation comprising salvia plebeia extract as effective component Download PDFInfo
- Publication number
- US20220362322A1 US20220362322A1 US17/773,243 US202017773243A US2022362322A1 US 20220362322 A1 US20220362322 A1 US 20220362322A1 US 202017773243 A US202017773243 A US 202017773243A US 2022362322 A1 US2022362322 A1 US 2022362322A1
- Authority
- US
- United States
- Prior art keywords
- cancer
- salvia plebeia
- cells
- extract
- plebeia extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241001354952 Salvia plebeia Species 0.000 title claims abstract description 79
- 235000009771 Salvia plebeia Nutrition 0.000 title claims abstract description 78
- 239000000284 extract Substances 0.000 title claims abstract description 74
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 70
- 239000000203 mixture Substances 0.000 title claims abstract description 25
- 230000002401 inhibitory effect Effects 0.000 title abstract description 11
- 230000035755 proliferation Effects 0.000 title abstract description 11
- 201000011510 cancer Diseases 0.000 claims abstract description 53
- 108010074708 B7-H1 Antigen Proteins 0.000 claims abstract description 21
- 102000008096 B7-H1 Antigen Human genes 0.000 claims abstract description 21
- 206010009944 Colon cancer Diseases 0.000 claims abstract description 20
- 208000029742 colonic neoplasm Diseases 0.000 claims abstract description 17
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 16
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 16
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 16
- 201000005202 lung cancer Diseases 0.000 claims abstract description 16
- 208000020816 lung neoplasm Diseases 0.000 claims abstract description 16
- 238000000034 method Methods 0.000 claims description 29
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 22
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 20
- 239000002246 antineoplastic agent Substances 0.000 claims description 18
- 230000001093 anti-cancer Effects 0.000 claims description 16
- 238000000605 extraction Methods 0.000 claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 208000035475 disorder Diseases 0.000 claims description 10
- 230000005746 immune checkpoint blockade Effects 0.000 claims description 10
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims description 8
- 239000013543 active substance Substances 0.000 claims description 8
- 239000002671 adjuvant Substances 0.000 claims description 8
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 7
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 7
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 7
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 7
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 4
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 4
- 108010092160 Dactinomycin Proteins 0.000 claims description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims description 4
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims description 4
- 229960000640 dactinomycin Drugs 0.000 claims description 4
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 4
- 229960001904 epirubicin Drugs 0.000 claims description 4
- 229960004857 mitomycin Drugs 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 3
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims description 3
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 201000000849 skin cancer Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 108010006654 Bleomycin Proteins 0.000 claims description 2
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims description 2
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 claims description 2
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims description 2
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims description 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 2
- 229930192392 Mitomycin Natural products 0.000 claims description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 2
- YJQPYGGHQPGBLI-UHFFFAOYSA-N Novobiocin Natural products O1C(C)(C)C(OC)C(OC(N)=O)C(O)C1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-UHFFFAOYSA-N 0.000 claims description 2
- 229930012538 Paclitaxel Natural products 0.000 claims description 2
- 206010040047 Sepsis Diseases 0.000 claims description 2
- 229960001686 afatinib Drugs 0.000 claims description 2
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 claims description 2
- 230000032683 aging Effects 0.000 claims description 2
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 claims description 2
- 229960001220 amsacrine Drugs 0.000 claims description 2
- 229960004395 bleomycin sulfate Drugs 0.000 claims description 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 2
- 229940127093 camptothecin Drugs 0.000 claims description 2
- 229960004562 carboplatin Drugs 0.000 claims description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 2
- 229960004316 cisplatin Drugs 0.000 claims description 2
- 229960000975 daunorubicin Drugs 0.000 claims description 2
- CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 claims description 2
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims description 2
- 229960003668 docetaxel Drugs 0.000 claims description 2
- 229960004679 doxorubicin Drugs 0.000 claims description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 2
- 229960001433 erlotinib Drugs 0.000 claims description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 2
- 229960005420 etoposide Drugs 0.000 claims description 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 2
- 229960002584 gefitinib Drugs 0.000 claims description 2
- 229960000908 idarubicin Drugs 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 229960004768 irinotecan Drugs 0.000 claims description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 2
- 201000008906 kidney fibrosarcoma Diseases 0.000 claims description 2
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 claims description 2
- 229960002950 novobiocin Drugs 0.000 claims description 2
- YJQPYGGHQPGBLI-KGSXXDOSSA-N novobiocin Chemical compound O1C(C)(C)[C@H](OC)[C@@H](OC(N)=O)[C@@H](O)[C@@H]1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-KGSXXDOSSA-N 0.000 claims description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 2
- 229960001756 oxaliplatin Drugs 0.000 claims description 2
- 229960001592 paclitaxel Drugs 0.000 claims description 2
- 229960003171 plicamycin Drugs 0.000 claims description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims description 2
- 229960001278 teniposide Drugs 0.000 claims description 2
- WUIABRMSWOKTOF-OYALTWQYSA-O 3-[[2-[2-[2-[[(2s,3r)-2-[[(2s,3s,4r)-4-[[(2s,3r)-2-[[6-amino-2-[(1s)-3-amino-1-[[(2s)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2r,3s,4s,5r,6r)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)ox Chemical compound OS(O)(=O)=O.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C WUIABRMSWOKTOF-OYALTWQYSA-O 0.000 claims 1
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- 190000008236 carboplatin Chemical compound 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 84
- 210000001744 T-lymphocyte Anatomy 0.000 abstract description 31
- 238000003501 co-culture Methods 0.000 abstract description 24
- 230000000694 effects Effects 0.000 abstract description 21
- 230000004611 cancer cell death Effects 0.000 abstract description 11
- 230000003993 interaction Effects 0.000 abstract description 5
- 238000002360 preparation method Methods 0.000 description 31
- 238000011282 treatment Methods 0.000 description 19
- 230000034994 death Effects 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 229940124597 therapeutic agent Drugs 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 235000013402 health food Nutrition 0.000 description 6
- 210000002865 immune cell Anatomy 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 230000037396 body weight Effects 0.000 description 5
- 238000002512 chemotherapy Methods 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000001959 radiotherapy Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 230000003833 cell viability Effects 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 230000035899 viability Effects 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 3
- 102000008070 Interferon-gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 101001117316 Mus musculus Programmed cell death 1 ligand 1 Proteins 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 238000011319 anticancer therapy Methods 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 230000002860 competitive effect Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229960003130 interferon gamma Drugs 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 2
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000008512 biological response Effects 0.000 description 2
- 239000004067 bulking agent Substances 0.000 description 2
- 235000001046 cacaotero Nutrition 0.000 description 2
- 229940022399 cancer vaccine Drugs 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 210000004696 endometrium Anatomy 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000001794 hormone therapy Methods 0.000 description 2
- 238000000185 intracerebroventricular administration Methods 0.000 description 2
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 2
- 229960003511 macrogol Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- FHHSEFRSDKWJKJ-UHFFFAOYSA-N nepetin Chemical compound C=1C(=O)C2=C(O)C(OC)=C(O)C=C2OC=1C1=CC=C(O)C(O)=C1 FHHSEFRSDKWJKJ-UHFFFAOYSA-N 0.000 description 2
- -1 olive oil Chemical compound 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- DMXHXBGUNHLMQO-UHFFFAOYSA-N pedaliin Natural products C1=C2OC(C=3C=C(O)C(O)=CC=3)=CC(=O)C2=C(O)C(OC)=C1OC1OC(CO)C(O)C(O)C1O DMXHXBGUNHLMQO-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000003799 water insoluble solvent Substances 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- WUIABRMSWOKTOF-OYALTWQYSA-N 3-[[2-[2-[2-[[(2s,3r)-2-[[(2s,3s,4r)-4-[[(2s,3r)-2-[[6-amino-2-[(1s)-3-amino-1-[[(2s)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2r,3s,4s,5r,6r)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)ox Chemical compound OS([O-])(=O)=O.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C WUIABRMSWOKTOF-OYALTWQYSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- GCLAFEGUXXHIFT-IWLDQSELSA-N Homoplantaginin Chemical compound C1=C2OC(C=3C=CC(O)=CC=3)=CC(=O)C2=C(O)C(OC)=C1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GCLAFEGUXXHIFT-IWLDQSELSA-N 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 231100000416 LDH assay Toxicity 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 240000002769 Morchella esculenta Species 0.000 description 1
- 235000002779 Morchella esculenta Nutrition 0.000 description 1
- 101000611935 Mus musculus Programmed cell death protein 1 Proteins 0.000 description 1
- DMXHXBGUNHLMQO-IWLDQSELSA-N Nepitrin Chemical compound C1=C2OC(C=3C=C(O)C(O)=CC=3)=CC(=O)C2=C(O)C(OC)=C1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O DMXHXBGUNHLMQO-IWLDQSELSA-N 0.000 description 1
- 239000012269 PD-1/PD-L1 inhibitor Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 1
- UWARRXZVZDFPQU-UHFFFAOYSA-N Sorbifolin Natural products C=1C(=O)C=2C(O)=C(O)C(OC)=CC=2OC=1C1=CC=C(O)C=C1 UWARRXZVZDFPQU-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000000611 antibody drug conjugate Substances 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 229940049595 antibody-drug conjugate Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 231100000481 chemical toxicant Toxicity 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- IHFBPDAQLQOCBX-UHFFFAOYSA-N hispidulin Chemical compound C=1C(=O)C2=C(O)C(OC)=C(O)C=C2OC=1C1=CC=C(O)C=C1 IHFBPDAQLQOCBX-UHFFFAOYSA-N 0.000 description 1
- OETSANFHEJPBHW-UHFFFAOYSA-N hispidulin Natural products COc1cc2c(cc1O)oc(cc2=O)-c1ccc(O)cc1 OETSANFHEJPBHW-UHFFFAOYSA-N 0.000 description 1
- 102000048776 human CD274 Human genes 0.000 description 1
- 102000048362 human PDCD1 Human genes 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000002843 lactate dehydrogenase assay Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940121653 pd-1/pd-l1 inhibitor Drugs 0.000 description 1
- 229920003175 pectinic acid Polymers 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- the present invention relates to a composition for inhibiting tumor proliferation comprising Salvia plebeia extract as an effective component.
- a target anti-cancer agent which is the second-generation anti-cancer agent for selectively attacking cancer cells instead of normal cells, has been developed. It is accordingly expected that the adverse effects of the first-generation anti-cancer agent can be minimized.
- the anti-cancer agent is characterized in that it exhibits its therapeutic effect by acting only on a cancer-causing protein to selectively inhibit the cancer cells.
- cancer-causing protein and the protein showing the therapeutic effect are different from each other depending on the type of cancer.
- cancer cells based on a mechanism of acquiring resistance to a target anti-cancer agent, cancer cells have the “immune cell evasion property” for causing mutation so that the cancer cells themselves do not become a target of the target anti-cancer agent. Accordingly, there may be a case in which the target anti-cancer agent is not able to recognize the cancer cells.
- the third-generation immune anti-cancer agent is currently developed by which problems associated with the adverse effects and resistance caused by anti-cancer therapy are reduced and remembering and attacking the cancer cells by immune cells are continuously achieved even after the termination of drug administration.
- the immune anti-cancer therapy is a treatment method of activating the immune system of a human body so as to enhance the autoimmunity and enable immune cells to attack cancer cells. As such, by focusing on the activity of immune cells, the immune anti-cancer agent is to awaken the “potential (of immune cells) for attacking cancer cells.”
- the immune anti-cancer agent can be categorized into an immune checkpoint inhibitor, an immune cell therapeutic agent, a therapeutic antibody, and an anti-cancer vaccine.
- Immune checkpoint inhibitor is an anti-cancer agent for attacking cancer cells based on blockage of the activity of immune checkpoint protein and activation of T cells.
- An antibody recognizing CTLA-4, PD-1, or PD-L1 is mainly used as an immune checkpoint inhibitor.
- an anti-cancer agent for enhancing the cell immunity mention can be made of an NK cell therapeutic agent, a T cell therapeutic agent, a CAR-T cell therapeutic agent, and the like.
- Therapeutic antibody is to attack cancer cells as a drug compound is released upon binding of an antibody drug conjugate to cancer cells.
- anti-cancer vaccine is an immunotherapy for attacking cancer cells according to activation of the immunity in human body, which is achieved by administering, to a cancer patient, a tumor-specific antigen presents in cancer cells or a protein/peptide molecule for enhancing the overall immune response.
- Salvia plebeia is Salvia plebeia R. Br. plant belonging to Labiatae , and it is also called morel cabbage, chongwacho, macho, gwadongchong, sooyangee, or the like. It is known to contain, in addition to flavonoids, homoplantaginin, hispidulin, eupafolin, and eupafolin-7-glucoside, components like phenolic material, essential oil, and saponin.
- a composition for preventing or treating respiratory inflammatory disease comprising specific crude extract or purified fraction isolated from Salvia plebeia as an effective component is described in Korean Patent Publication No. 2016-0146007.
- Korean Patent Publication No. 2011-0078672 a cosmetic composition comprising Salvia plebeia extract as an effective component is disclosed.
- a composition for inhibiting tumor proliferation comprising Salvia plebeia extract as an effective component as it is described in the present invention.
- the present invention is devised under the circumstances that are described above, and the present invention provides a composition for inhibiting tumor proliferation comprising Salvia plebeia extract as an effective component. It was found that, as a result of binding to PD-L1 present on a surface of cancer cell or PD-1 present on a surface of immune T cell, Salvia plebeia extract blocks the interaction between cancer cell and PD-1 present on a surface of T cell to activate T cells, thus exhibiting an inhibitory effect on tumor proliferation. It was also found that, according to co-culture of cells of colon cancer, breast cancer, or lung cancer with immune T cells, the group treated with Salvia plebeia extract showed higher effect of causing cancer cell death, and the present invention is completed accordingly.
- the present invention provides a functional health food composition for immune checkpoint inhibition comprising Salvia plebeia extract as an effective component.
- the present invention further provides a pharmaceutical composition for preventing or treating a disorder related to immune checkpoint inhibition comprising Salvia plebeia extract as an effective component.
- the present invention further provides an anti-tumor pharmaceutical composition
- an anti-tumor pharmaceutical composition comprising anti-cancer active agent and Salvia plebeia extract as an effective component.
- the present invention still further provides anti-cancer adjuvant comprising Salvia plebeia extract as an effective component.
- the present invention is devised under the circumstances that are described in the above, and the present invention relates to a composition for inhibiting tumor proliferation comprising Salvia plebeia extract as an effective component. It was found that, as a result of blocking the interaction (i.e., binding) between PD-L1 present on a surface cancer cell and PD-1 present on a surface of immune T cell, Salvia plebeia extract as an effective component of the present invention activates immune T cells and thus exhibits an inhibitory effect on tumor proliferation. It was also found that, according to co-culture of cells of colon cancer, breast cancer, or lung cancer with T cells, the group treated with Salvia plebeia extract shows higher effect of causing cancer cell death.
- FIG. 1 shows the concentration-dependent inhibition of PD-1/PD-L1 binding when PD-1 binding is allowed to occur after treating a plate, which has been previously coated with PD-L1, with 0.1 to 100 ⁇ g/ml anti-PD-L1. ** and *** indicate that, compared to the group without anti-PD-L1 treatment, the group treated with 0.1 to 100 ⁇ g/ml anti-PD-L1 has a statistically significant decrease in the PD-1/PD-L1 binding (**; p ⁇ 0.01, and ***; p ⁇ 0.001).
- FIG. 2 shows the concentration-dependent inhibition of PD-1/PD-L1 binding when PD-1 binding is allowed to occur after treating a plate, which has been previously coated with PD-L1, with 10 to 500 ⁇ g/ml Salvia plebeia extract. *** indicates that, compared to the group without any Salvia plebeia extract treatment, the group treated with Salvia plebeia extract has a statistically significant decrease in the PD-1/PD-L1 binding (p ⁇ 0.001).
- FIG. 3 shows the result indicating that T cell-mediated death of colon cancer cells is enhanced by Salvia plebeia extract.
- A of FIG. 3 is the result of FACS for analyzing hPD-L1 expression in mouse colon cancer cells MC38 (CON) or MC38 cells in which mPD-L1 is replaced by hPD-L1 (hPD-L1-MC38).
- B of FIG. 3 is the result of determining the death of hPD-L1-MC38 cancer cells in Salvia plebeia extract (SPE) treatment group when hPD-L1-MC38 cells as cancer cells and spleen cells containing T cell (SP) are co-cultured.
- SPE Salvia plebeia extract
- FIG. 3 is a photographic image showing the induced death of the colon cancer cells (MC38) in the group treated with 25 ⁇ g/ml Salvia plebeia extract.
- FIG. 4 shows the death of cancer cells in the Salvia plebeia extract (SPE) treatment group when human colon cancer cells (HCT116) are co-cultured with T cells.
- SPE Salvia plebeia extract
- HCT116 human colon cancer cells
- (B) of FIG. 4 is the result of measuring the amount of cancer cells of(A) of FIG. 4 , in which *, **, and *** indicate that, compared to CON, the group treated with PD-L1 Ab (antibody) or Salvia plebeia extract exhibits a statistically significant increase in cancer cell death (*; p ⁇ 0.05, **; p ⁇ 0.01, and ***; p ⁇ 0.001).
- FIG. 5 shows the result of determining, when breast cancer cells (MCF-7) and T cells are co-cultured, the viability of cancer cells after the treatment with Salvia plebeia extract (SPE).
- A) of FIG. 5 shows the result after co-culture of the breast cancer cells (MCF-7) and T cells at a ratio of 1:2
- B) of FIG. 5 shows the result after co-culture of the breast cancer cells (MCF-7) and T cells at a ratio of 1:5.
- ** and *** indicate that, compared to the group without any treatment with Salvia plebeia extract, the group treated with Salvia plebeia extract has a statistically significant decrease in cancer cell viability (**; p ⁇ 0.01, and ***; p ⁇ 0.001).
- FIG. 6 shows the result of determining, when lung cancer cells (A549) and T cells are co-cultured, the viability of cancer cells after the treatment with Salvia plebeia extract (SPE).
- a of FIG. 6 shows the result after co-culture of the lung cancer cells (A549) and
- T cells at a ratio of 1:2 and (B) of FIG. 6 shows the result after co-culture of the lung cancer cells (A549) and T cells at a ratio of 1:5. ** and *** indicate that, compared to the group without any treatment with Salvia plebeia extract, the group treated with Salvia plebeia extract has a statistically significant decrease in cancer cell viability (**; p ⁇ 0.01, and ***; p ⁇ 0.001).
- FIG. 7 shows the result of determining, after administering the Salvia plebeia extract (SPE) of the present invention, the body weight (B) and the reduction in tumor size (C) according to the passage of time (A), in which the test was made with an animal model of colon cancer.
- SPE Salvia plebeia extract
- C tumor size
- the present invention relates to a functional health food composition for immune checkpoint inhibition comprising Salvia plebeia extract as an effective component.
- the Salvia plebeia extract can be produced by a method including the following steps:
- the extraction solvent of the above step (1) is preferably selected from water, C 1 -C 4 lower alcohol, and a mixture thereof. It is more preferably C 1 -C 4 lower alcohol and even more preferably 70% (v/v) ethanol, but not limited thereto.
- any kind of common methods that are generally known as extraction method in the pertinent art e.g., filtration, hot water extraction, impregnation extraction, extraction by reflux condensation, and ultrasonic extraction, can be used.
- the extraction is carried out by adding an extraction solvent in an amount of 1 to 20 times the weight of Salvia plebeia . More preferably, the extraction solvent is added in an amount of 5 to 15 times the weight of Salvia plebeia .
- the extraction temperature is preferably between 4° C. and 50° C., but it is not limited thereto.
- the extraction time is preferably between 0.5 hour and 10 hours, and more preferably between 0.5 hour and 5 hours, but it is not limited thereto.
- the concentration of the step (3) in the above method uses a vacuum rotary condenser or a vacuum rotary evaporator, but it is not limited thereto.
- the drying is preferably carried out by drying under reduced pressure, drying under vacuum, drying under boiling, spray drying, or freeze-drying, but it is not limited thereto.
- the Salvia plebeia extract is characterized in that it has PD-L1 or PD-1 as a target.
- the cancer cell is preferably a cancer cell originating from any cancer selected from colon cancer, breast cancer, lung cancer, melanoma, liver cancer, stomach cancer, colorectal cancer, skin cancer, bladder cancer, prostate cancer, ovary cancer, cervical cancer, thyroid cancer, kidney cancer, fibrosarcoma, and leukemia, but it is not limited thereto.
- Salvia plebeia extract may be directly added to the functional health food composition of the present invention, or it may be used with other food product or food ingredient, and it can be suitably used according to a common method.
- Type of the functional health food composition is not particularly limited. Examples of the food to which the Salvia plebeia extract can be added include meat, sausage, bread, chocolate, candies, snacks, biscuits, pizza, ramen, other noodles, gums, dairy products including ice cream, various kinds of soup, beverage, tea, drink, alcohol beverage, and vitamin complex, and all functional health food products in general sense are included therein.
- health drink containing the composition of the present invention may comprise various flavoring agents and natural carbohydrates as an additional component.
- the natural carbohydrates include monosaccharides like glucose and fructose, disaccharides like maltose and sucrose, polysaccharides like dextrin and cyclodextrin, and sugar alcohols like xylitol, sorbitol, and erythritol.
- a sweetening agent natural sweetening agent like thaumatin and stevia extract and synthetic sweetening agent like saccharine and aspartame can be used.
- Amount of the natural carbohydrates is generally about 0.01 g to 0.04 g, and preferably about 0.02 g to 0.03 g relative to 100 g of the composition of the present invention.
- the functional health food composition of the present invention may further comprise, in addition to the aforementioned effective component, various nutritional supplements, a vitamin, an electrolyte, a flavor, a coloring agent, pectinic acid and a salt thereof, alginic acid and a salt thereof, an organic acid, a protective colloidal thickening agent, a pH adjusting agent, a stabilizer, a preservative, glycerin, alcohol, and a carbonating agent used for carbonated drink.
- fruit juice or fruit pulp for producing vegetable drink may be additionally comprised.
- Those ingredients may be used either singly or in combination thereof.
- Amount of the above various additives is not critical, but it is generally selected from a range of about 0.01 to 2 parts by weight relative to 100 parts by weight of the composition of the present invention.
- the present invention further relates to a pharmaceutical composition for preventing or treating a disorder related to immune checkpoint inhibition comprising Salvia plebeia extract as an effective component.
- the disorder related to immune checkpoint inhibition is preferably cancer, infection, sepsis, or immune aging. It is more preferably cancer, but not limited thereto.
- the cancer is the same as defined in the above.
- the present invention further relates to an anti-tumor pharmaceutical composition
- an anti-tumor pharmaceutical composition comprising an anti-cancer active agent and Salvia plebeia extract as an effective component.
- the anti-cancer active agent is preferably an anti-cancer agent or an immune checkpoint inhibitor, but it is not limited thereto.
- the anti-cancer agent is preferably one or more selected from actinomycin D, bleomycin sulfate, daunomycin, daunorubicin, doxorubicin, epirubicin, idarubicin, mitomycin, mitomycin-C, mithramycin, irinotecan, camptothecin, novobiocin, epirubicin, dactinomycin, amsacrine, teniposide, etoposide, cisplatin, carboplatin, oxaliplatin, paclitaxel, docetaxel, gefitinib, erlotinib, and afatinib
- the immune checkpoint inhibitor is preferably anti PD-L1 antibody, anti PD-1 antibody, anti CD-80 antibody, or anti CTLA-4 antibody, but it is not limited thereto.
- the pharmaceutical composition of the present invention may be in various types of preparation such as oral preparation or parenteral preparation.
- the preparation is made by using a diluent or a vehicle such as filler, bulking agent, binding agent, moisturizing agent, disintegrating agent, or surfactant that are commonly used for producing a preparation.
- a diluent or a vehicle such as filler, bulking agent, binding agent, moisturizing agent, disintegrating agent, or surfactant that are commonly used for producing a preparation.
- the solid preparation for oral administration include a tablet, a pill, a powder, a granule, and a capsule.
- the solid preparation is produced by mixing at least one compound with one or more vehicles such as starch, calcium carbonate, sucrose, lactose, or gelatin.
- a lubricating agent such as magnesium stearate or talc is also used.
- liquid preparation for oral administration a suspension, a solution preparation for internal use, an emulsion, a syrup preparation, or the like can be mentioned.
- a vehicle such as moisturizing agent, sweetening agent, aromatic agent, or preservatives may be included.
- Examples of a preparation for parenteral administration include a sterilized aqueous solution, a non-soluble preparation, a suspension preparation, an emulsion preparation, a freeze-dried preparation, and a suppository preparation.
- a water insoluble solvent or a suspending preparation propylene glycol, polyethylene glycol, or vegetable oil such as olive oil, and injectable ester such as ethylolate can be used.
- a base for a suppository preparation witepsol, macrogol, tween 61 , cacao fat, laurin fat, glycerol, gelatin, or the like can be used.
- the pharmaceutical composition of the present invention can be administered either orally or parenterally.
- parenteral administration it is preferable to choose external application on skin, or intraperitoneal, rectal, intravenous, muscular, subcutaneous, endometrium injection, or intracerebroventricular injection.
- the pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount.
- pharmaceutically effective amount means an amount sufficient for treating a disorder at reasonable benefit-risk ratio that can be applied for a medical treatment.
- the effective dose level may be determined based on a type or severeness of a disorder of a patient, activity of a pharmaceutical, sensitivity to a pharmaceutical, administration period, administration route, excretion ratio, time period for therapy, elements including a pharmaceutical used in combination, and other elements that are well known in the medical field.
- the composition of the present invention can be administered as a separate therapeutic agent, or it can be used in combination with other therapeutic agent. It can be administered in order or simultaneously with a conventional therapeutic agent. It can be also administered as single-dose or multi-dose. It is important to administer an amount which allows obtainment of the maximum effect with minimum dose while considering all of the aforementioned elements without having any side effect, and the dosage can be easily determined by a person skilled in the pertinent art.
- the dosage of the composition of the present invention may vary depending on body weight, age, sex, health state, diet of a patient, administration period, administration method, excretion rate, and severeness of disorder.
- the daily dosage is, in terms of the amount of Salvia plebeia extract, 0.01 to 2,000 mg/kg, preferably 30 to 500 mg/kg, and more preferably 50 to 300 mg/kg, and it can be administered 1 to 6 times per day.
- the pharmaceutical composition of the present invention may be used either singly, or in combination with other treatment methods including surgery, radiation therapy, hormone therapy, chemotherapy, antibody therapy, and a method of using biological response modifier.
- the present invention still further relates to an anti-cancer adjuvant comprising Salvia plebeia extract as an effective component.
- the anti-cancer adjuvant may comprise, in addition to the Salvia plebeia extract, one or more types of an effective component which exhibits similar or even identical effect to the extract.
- the anti-cancer adjuvant may be administered either orally or parenterally.
- parenteral administration it may be administered via intraperitoneal injection, intrarectal injection, subcutaneous injection, intravenous injection, muscular injection, endometrium injection, intracerebroventricular injection, or intrathoracic injection, and it can be used in the form of a common pharmaceutical preparation.
- the anti-cancer adjuvant may be used either singly, or in combination with other methods including surgery, radiation therapy, hormone therapy, chemotherapy, and a method of using biological response modifier.
- the dosage of the anti-cancer adjuvant is about 0.0001 to 100 mg/kg, and preferably 0.001 to 10 mg/kg per day, and the administration can be made once a day, or several times a day with divided portion.
- the dosage is within a broad range depending on body weight, age, sex, health state, and diet of a patient, administration period and administration method, excretion rate, and severeness of disorder.
- the anti-cancer adjuvant of the present invention may be administered parenterally in various preparation types, and in case of producing a preparation, the preparation can be made by using a diluent or a vehicle like a filling agent, a bulking agent, a binding agent, a wetting agent, a disintegrating agent, and a surfactant that are commonly used.
- a preparation for parenteral administration include a sterilized aqueous solution, a non-soluble preparation, a suspension preparation, an emulsion preparation, a freeze-dried preparation, and a suppository preparation.
- a water insoluble solvent or a suspending preparation propylene glycol, polyethylene glycol, or vegetable oil such as olive oil, and injectable ester such as ethylolate can be used.
- a base for a suppository preparation witepsol, macrogol, tween 61, cacao fat, laurin fat, glycerol, gelatin, or the like can be used.
- Salvia plebeia extract After drying 10 g of Salvia plebeia , 70% (v/v) ethanol (100 ml) was added thereto as a solvent. Reflux extraction of the mixture was carried out three times for 2 hours followed by concentration under reduced pressure to prepare Salvia plebeia extract.
- concentration-dependent binding of the ethanol extract of Salvia plebeia to PD-L1 was determined to examine the blockage of the interaction with PD-1.
- the competitive ELISA analysis was carried out according to the manufacturer's protocol using the PD-1/PD-L1 inhibitor screening kit.
- Recombinant human PD-L1 (1 ⁇ g/ml) dissolved in PBS was coated overnight on a 96-well plate.
- the 96-well plate was then washed with PBS containing 0.1% Tween (PBS-T) and blocked at room temperature for 1 hour with PBS containing 2% (w/v) BSA followed by washing again.
- PBS-T 0.1% Tween
- FIG. 1 it was found that PD-1/PD-L1 binding was inhibited in concentration dependent manner, and Salvia plebeia extract inhibits, with statistical significance, PD-1/PD-L1 binding in concentration dependent manner ( FIG. 2 ). Based on this result, it was recognized that T cell activation is promoted via immune checkpoint inhibition, and thus the effect of inhibiting tumor proliferation against cancer cells is exhibited.
- hPD-L1 On surface of MC38 cells, flow cytometry was carried out. Specifically, to detect the surface expression of hPD-L1 (CD274) in MC38 cells, cells were suspended in phosphate-buffered physiological saline (PBS) with 0.2% bovine serum albumin. Then, the cells were treated on ice with ePC-conjugated anti-human PD-L1 antibody or APC-conjugated mouse IgG 1 as an isotype control group followed by incubation for 30 minutes. Thereafter, the cells were washed with PBS and examined using CytoFLEX flow cytometer (Beckman, Brea, Calif., USA). The obtained data were analyzed using FlowJo Software version v10.
- CCK assay Cell viability was measured by using CCK assay. On a 96 well plate, cells were spread in an amount of 1 ⁇ 10 4 cells/well and cultured overnight. After that, Salvia plebeia extract was added at each different concentration. CCK solution (10 ⁇ l) was then added and the plate was incubated for 2 hours at 37° C. Thereafter, color intensity was measured at 450 nm by using a microplate reader.
- LDH activity and cancer cell death in Salvia plebeia extract (SPE) treatment group were determined after co-culture of human colon cancer cells (HCT116) and T cells.
- HCT116 colon cancer cells
- T cells having overexpressed PD-1 were aliquoted, in an amount of 1 ⁇ 10 5 cells/well, to the 96 well plate adhered with colon cancer cells, Salvia plebeia extract (12.5 or 25 ⁇ g/ml) was added, and co-culture was carried out for 72 hours.
- the top part of the culture broth was aliquoted to a fresh 96 well plate and reagents for LDH assay were added to have a reaction. Once the reaction is over, a solution for terminating the reaction was added, and the absorbance at 540 nm was measured for each sample.
- breast cancer cells which have been treated with 10 ng/ml interferon gamma were spread on a 96 well plate in an amount of 5 ⁇ 10 4 cells/well and cultured for 18 hours to have adhesion on the plate bottom.
- T cells having overexpressed PD-1 were aliquoted, in an amount of 1 ⁇ 10 5 cells/well for co-culture with a ratio of 1:2 or 2.5 ⁇ 10 5 cells/well for co-culture with a ratio of 1:5, to the 96 well plate adhered with breast cancer cells, Salvia plebeia extract (12.5, 25, 50 or 100 ⁇ g/ml) was added, and co-culture was carried out for 72 hours.
- CCK solution 100 was added followed by incubation for 2 hours at 37° C. Absorbance at 450 nm was then measured for each sample using microplate.
- lung cancer cells (A549) which have been treated with 10 ng/ml interferon gamma were spread on a 96 well plate in an amount of 5 ⁇ 10 4 cells/well and cultured for 18 hours to have adhesion on the plate bottom.
- T cells having overexpressed PD-1 were aliquoted, in an amount of 1 ⁇ 10 5 cells/well for co-culture with a ratio of 1:2 or 2.5 ⁇ 10 5 cells/well for co-culture with a ratio of 1:5, to the 96 well plate adhered with lung cancer cells, Salvia plebeia extract (12.5, 25, 50 or 100 ⁇ g/ml) was added, and co-culture was carried out for 72 hours.
- CCK solution (10 ⁇ l) was added followed by incubation for 2 hours at 37° C. Absorbance at 450 nm was then measured for each sample using microplate.
- MC38 cells mouse colon cancer cells obtained by removing mouse PD-L1 (mPD-L1) and replacing it with human PD-1 (hPD-L1) were injected to the animal.
- aPD-1 (positive control) or Salvia plebeia extract 100 or 300 mg/kg was administered with a time interval shown in FIG. 7 . Body weight of the animal and tumor size were then measured.
- the tumor size has been reduced with statistical significance in the Salvia plebeia extract administration group of the present invention and the positive control group when compared to the group induced to have cancer (i.e., vehicle), while there is no clear change in the mouse body weight.
Abstract
A composition according to an embodiment of the present disclosure can be used for inhibiting tumor proliferation and includes a Salvia plebeia extract as an effective component. It was found that, as a result of binding to PD-L1 present on a surface of cancer cell, Salvia plebeia extract blocks the interaction between cancer cell and PD-1 present on a surface of immune T cell to activate T cells and exhibit an inhibitory effect on tumor proliferation. It was also found that, according to co-culture of cells of colon cancer, breast cancer, or lung cancer with T cells, the group treated with Salvia plebeia extract shows higher effect of causing cancer cell death.
Description
- This application claims benefit under 35 U.S.C. 119, 120, 121, or 365(c), and is a National Stage entry from International Application No. PCT/KR2020/013292, filed Sep. 29, 2020, which claims priority to the benefit of Korean Patent Application No. 10-2019-0137681 filed in the Korean Intellectual Property Office on Oct. 31, 2019, the entire contents of which are incorporated herein by reference.
- The present invention relates to a composition for inhibiting tumor proliferation comprising Salvia plebeia extract as an effective component.
- As a common anti-cancer therapy for overcoming cancer, tumorectomy is known. For reducing tumor size before surgery, causing death of cancer cells which still remain after surgery, or preventing recurrence of cancer, radiation therapy and chemotherapy are also employed in combination with surgery. Radiation therapy and chemotherapy, which are called as the first-generation anti-cancer agent, are methods of inducing cancer cell death by interfering the pathway of cancer cells to unlimited division and proliferation. However, as the radiation therapy requires high energy beam radiation, a problem occurs in that not only the DNA damage of cancer cell but also death of normal cell is caused.
- Moreover, even in case of the chemotherapy involving administration of toxic chemicals for inhibiting cell division process, division of normal cells is also inhibited instead of specific inhibition of the cancer cell division. As such, there is a problem of having serious adverse effects like reduced number of white blood cells, hair loss, and the like. To overcome those problems, a target anti-cancer agent, which is the second-generation anti-cancer agent for selectively attacking cancer cells instead of normal cells, has been developed. It is accordingly expected that the adverse effects of the first-generation anti-cancer agent can be minimized.
- Meanwhile, the anti-cancer agent is characterized in that it exhibits its therapeutic effect by acting only on a cancer-causing protein to selectively inhibit the cancer cells.
- However, the cancer-causing protein and the protein showing the therapeutic effect are different from each other depending on the type of cancer. Thus, it is necessary to use an anti-cancer agent that is a match with the specific type of a target protein. Moreover, based on a mechanism of acquiring resistance to a target anti-cancer agent, cancer cells have the “immune cell evasion property” for causing mutation so that the cancer cells themselves do not become a target of the target anti-cancer agent. Accordingly, there may be a case in which the target anti-cancer agent is not able to recognize the cancer cells.
- As such, the third-generation immune anti-cancer agent is currently developed by which problems associated with the adverse effects and resistance caused by anti-cancer therapy are reduced and remembering and attacking the cancer cells by immune cells are continuously achieved even after the termination of drug administration.
- The immune anti-cancer therapy is a treatment method of activating the immune system of a human body so as to enhance the autoimmunity and enable immune cells to attack cancer cells. As such, by focusing on the activity of immune cells, the immune anti-cancer agent is to awaken the “potential (of immune cells) for attacking cancer cells.”
- The immune anti-cancer agent can be categorized into an immune checkpoint inhibitor, an immune cell therapeutic agent, a therapeutic antibody, and an anti-cancer vaccine. Immune checkpoint inhibitor is an anti-cancer agent for attacking cancer cells based on blockage of the activity of immune checkpoint protein and activation of T cells. An antibody recognizing CTLA-4, PD-1, or PD-L1 is mainly used as an immune checkpoint inhibitor. As an anti-cancer agent for enhancing the cell immunity, mention can be made of an NK cell therapeutic agent, a T cell therapeutic agent, a CAR-T cell therapeutic agent, and the like. Therapeutic antibody is to attack cancer cells as a drug compound is released upon binding of an antibody drug conjugate to cancer cells. Furthermore, anti-cancer vaccine is an immunotherapy for attacking cancer cells according to activation of the immunity in human body, which is achieved by administering, to a cancer patient, a tumor-specific antigen presents in cancer cells or a protein/peptide molecule for enhancing the overall immune response.
- Salvia plebeia is Salvia plebeia R. Br. plant belonging to Labiatae, and it is also called morel cabbage, chongwacho, mamacho, gwadongchong, sooyangee, or the like. It is known to contain, in addition to flavonoids, homoplantaginin, hispidulin, eupafolin, and eupafolin-7-glucoside, components like phenolic material, essential oil, and saponin.
- As a study related to Salvia plebeia, a composition for preventing or treating respiratory inflammatory disease comprising specific crude extract or purified fraction isolated from Salvia plebeia as an effective component is described in Korean Patent Publication No. 2016-0146007. In addition, in Korean Patent Publication No. 2011-0078672, a cosmetic composition comprising Salvia plebeia extract as an effective component is disclosed. However, so far there is no disclosure of a composition for inhibiting tumor proliferation comprising Salvia plebeia extract as an effective component as it is described in the present invention.
- The present invention is devised under the circumstances that are described above, and the present invention provides a composition for inhibiting tumor proliferation comprising Salvia plebeia extract as an effective component. It was found that, as a result of binding to PD-L1 present on a surface of cancer cell or PD-1 present on a surface of immune T cell, Salvia plebeia extract blocks the interaction between cancer cell and PD-1 present on a surface of T cell to activate T cells, thus exhibiting an inhibitory effect on tumor proliferation. It was also found that, according to co-culture of cells of colon cancer, breast cancer, or lung cancer with immune T cells, the group treated with Salvia plebeia extract showed higher effect of causing cancer cell death, and the present invention is completed accordingly.
- To achieve the purpose described above, the present invention provides a functional health food composition for immune checkpoint inhibition comprising Salvia plebeia extract as an effective component.
- The present invention further provides a pharmaceutical composition for preventing or treating a disorder related to immune checkpoint inhibition comprising Salvia plebeia extract as an effective component.
- The present invention further provides an anti-tumor pharmaceutical composition comprising anti-cancer active agent and Salvia plebeia extract as an effective component.
- The present invention still further provides anti-cancer adjuvant comprising Salvia plebeia extract as an effective component.
- The present invention is devised under the circumstances that are described in the above, and the present invention relates to a composition for inhibiting tumor proliferation comprising Salvia plebeia extract as an effective component. It was found that, as a result of blocking the interaction (i.e., binding) between PD-L1 present on a surface cancer cell and PD-1 present on a surface of immune T cell, Salvia plebeia extract as an effective component of the present invention activates immune T cells and thus exhibits an inhibitory effect on tumor proliferation. It was also found that, according to co-culture of cells of colon cancer, breast cancer, or lung cancer with T cells, the group treated with Salvia plebeia extract shows higher effect of causing cancer cell death.
-
FIG. 1 shows the concentration-dependent inhibition of PD-1/PD-L1 binding when PD-1 binding is allowed to occur after treating a plate, which has been previously coated with PD-L1, with 0.1 to 100 μg/ml anti-PD-L1. ** and *** indicate that, compared to the group without anti-PD-L1 treatment, the group treated with 0.1 to 100 μg/ml anti-PD-L1 has a statistically significant decrease in the PD-1/PD-L1 binding (**; p<0.01, and ***; p<0.001). -
FIG. 2 shows the concentration-dependent inhibition of PD-1/PD-L1 binding when PD-1 binding is allowed to occur after treating a plate, which has been previously coated with PD-L1, with 10 to 500 μg/ml Salvia plebeia extract. *** indicates that, compared to the group without any Salvia plebeia extract treatment, the group treated with Salvia plebeia extract has a statistically significant decrease in the PD-1/PD-L1 binding (p<0.001). -
FIG. 3 shows the result indicating that T cell-mediated death of colon cancer cells is enhanced by Salvia plebeia extract. (A) ofFIG. 3 is the result of FACS for analyzing hPD-L1 expression in mouse colon cancer cells MC38 (CON) or MC38 cells in which mPD-L1 is replaced by hPD-L1 (hPD-L1-MC38). (B) ofFIG. 3 is the result of determining the death of hPD-L1-MC38 cancer cells in Salvia plebeia extract (SPE) treatment group when hPD-L1-MC38 cells as cancer cells and spleen cells containing T cell (SP) are co-cultured. *** indicates that, compared to the control group (CON), the group treated with SPE has a statistically significant decrease in cancer cell viability (p<0.001). (C) ofFIG. 3 is a photographic image showing the induced death of the colon cancer cells (MC38) in the group treated with 25 μg/ml Salvia plebeia extract. -
FIG. 4 shows the death of cancer cells in the Salvia plebeia extract (SPE) treatment group when human colon cancer cells (HCT116) are co-cultured with T cells. (A) ofFIG. 4 is the result of measuring the LDH activity of dead cancer cells that are present in co-culture supernatant, in which *** indicates that, compared to CON, the group treated with Salvia plebeia extract has a statistically significant increase in LDH activity (p<0.001). - (B) of
FIG. 4 is the result of measuring the amount of cancer cells of(A) ofFIG. 4 , in which *, **, and *** indicate that, compared to CON, the group treated with PD-L1 Ab (antibody) or Salvia plebeia extract exhibits a statistically significant increase in cancer cell death (*; p<0.05, **; p<0.01, and ***; p<0.001). -
FIG. 5 shows the result of determining, when breast cancer cells (MCF-7) and T cells are co-cultured, the viability of cancer cells after the treatment with Salvia plebeia extract (SPE). (A) ofFIG. 5 shows the result after co-culture of the breast cancer cells (MCF-7) and T cells at a ratio of 1:2, and (B) ofFIG. 5 shows the result after co-culture of the breast cancer cells (MCF-7) and T cells at a ratio of 1:5. ** and *** indicate that, compared to the group without any treatment with Salvia plebeia extract, the group treated with Salvia plebeia extract has a statistically significant decrease in cancer cell viability (**; p<0.01, and ***; p<0.001). -
FIG. 6 shows the result of determining, when lung cancer cells (A549) and T cells are co-cultured, the viability of cancer cells after the treatment with Salvia plebeia extract (SPE). (A) ofFIG. 6 shows the result after co-culture of the lung cancer cells (A549) and - T cells at a ratio of 1:2, and (B) of
FIG. 6 shows the result after co-culture of the lung cancer cells (A549) and T cells at a ratio of 1:5. ** and *** indicate that, compared to the group without any treatment with Salvia plebeia extract, the group treated with Salvia plebeia extract has a statistically significant decrease in cancer cell viability (**; p<0.01, and ***; p<0.001). -
FIG. 7 shows the result of determining, after administering the Salvia plebeia extract (SPE) of the present invention, the body weight (B) and the reduction in tumor size (C) according to the passage of time (A), in which the test was made with an animal model of colon cancer. *** indicates that, compared to the group with induced cancer (i.e., vehicle), the group administered with Salvia plebeia extract of the present invention or the positive control has a statistically significant decrease in tumor size (p<0.001). - The present invention relates to a functional health food composition for immune checkpoint inhibition comprising Salvia plebeia extract as an effective component. The Salvia plebeia extract can be produced by a method including the following steps:
- (1) carrying out extraction by adding an extraction solvent to Salvia plebeia;
- (2) filtering the extract of the step (1); and (3) concentrating under reduced pressure the filtered extract of the step (2) followed by drying to produce extract, but the method is not limited thereto.
- The extraction solvent of the above step (1) is preferably selected from water, C1-C4 lower alcohol, and a mixture thereof. It is more preferably C1-C4 lower alcohol and even more preferably 70% (v/v) ethanol, but not limited thereto.
- With regard to the production method, any kind of common methods that are generally known as extraction method in the pertinent art, e.g., filtration, hot water extraction, impregnation extraction, extraction by reflux condensation, and ultrasonic extraction, can be used. It is preferable that the extraction is carried out by adding an extraction solvent in an amount of 1 to 20 times the weight of Salvia plebeia. More preferably, the extraction solvent is added in an amount of 5 to 15 times the weight of Salvia plebeia. The extraction temperature is preferably between 4° C. and 50° C., but it is not limited thereto. Furthermore, the extraction time is preferably between 0.5 hour and 10 hours, and more preferably between 0.5 hour and 5 hours, but it is not limited thereto. It is preferable that the concentration of the step (3) in the above method uses a vacuum rotary condenser or a vacuum rotary evaporator, but it is not limited thereto. Furthermore, the drying is preferably carried out by drying under reduced pressure, drying under vacuum, drying under boiling, spray drying, or freeze-drying, but it is not limited thereto.
- The Salvia plebeia extract is characterized in that it has PD-L1 or PD-1 as a target. The cancer cell is preferably a cancer cell originating from any cancer selected from colon cancer, breast cancer, lung cancer, melanoma, liver cancer, stomach cancer, colorectal cancer, skin cancer, bladder cancer, prostate cancer, ovary cancer, cervical cancer, thyroid cancer, kidney cancer, fibrosarcoma, and leukemia, but it is not limited thereto.
- Salvia plebeia extract may be directly added to the functional health food composition of the present invention, or it may be used with other food product or food ingredient, and it can be suitably used according to a common method. Type of the functional health food composition is not particularly limited. Examples of the food to which the Salvia plebeia extract can be added include meat, sausage, bread, chocolate, candies, snacks, biscuits, pizza, ramen, other noodles, gums, dairy products including ice cream, various kinds of soup, beverage, tea, drink, alcohol beverage, and vitamin complex, and all functional health food products in general sense are included therein. Like common beverages, health drink containing the composition of the present invention may comprise various flavoring agents and natural carbohydrates as an additional component. Examples of the natural carbohydrates include monosaccharides like glucose and fructose, disaccharides like maltose and sucrose, polysaccharides like dextrin and cyclodextrin, and sugar alcohols like xylitol, sorbitol, and erythritol. As a sweetening agent, natural sweetening agent like thaumatin and stevia extract and synthetic sweetening agent like saccharine and aspartame can be used. Amount of the natural carbohydrates is generally about 0.01 g to 0.04 g, and preferably about 0.02 g to 0.03 g relative to 100 g of the composition of the present invention.
- The functional health food composition of the present invention may further comprise, in addition to the aforementioned effective component, various nutritional supplements, a vitamin, an electrolyte, a flavor, a coloring agent, pectinic acid and a salt thereof, alginic acid and a salt thereof, an organic acid, a protective colloidal thickening agent, a pH adjusting agent, a stabilizer, a preservative, glycerin, alcohol, and a carbonating agent used for carbonated drink. Other than those, fruit juice or fruit pulp for producing vegetable drink may be additionally comprised. Those ingredients may be used either singly or in combination thereof. Amount of the above various additives is not critical, but it is generally selected from a range of about 0.01 to 2 parts by weight relative to 100 parts by weight of the composition of the present invention.
- The present invention further relates to a pharmaceutical composition for preventing or treating a disorder related to immune checkpoint inhibition comprising Salvia plebeia extract as an effective component.
- The disorder related to immune checkpoint inhibition is preferably cancer, infection, sepsis, or immune aging. It is more preferably cancer, but not limited thereto. The cancer is the same as defined in the above.
- The present invention further relates to an anti-tumor pharmaceutical composition comprising an anti-cancer active agent and Salvia plebeia extract as an effective component.
- The anti-cancer active agent is preferably an anti-cancer agent or an immune checkpoint inhibitor, but it is not limited thereto. The anti-cancer agent is preferably one or more selected from actinomycin D, bleomycin sulfate, daunomycin, daunorubicin, doxorubicin, epirubicin, idarubicin, mitomycin, mitomycin-C, mithramycin, irinotecan, camptothecin, novobiocin, epirubicin, dactinomycin, amsacrine, teniposide, etoposide, cisplatin, carboplatin, oxaliplatin, paclitaxel, docetaxel, gefitinib, erlotinib, and afatinib, and the immune checkpoint inhibitor is preferably anti PD-L1 antibody, anti PD-1 antibody, anti CD-80 antibody, or anti CTLA-4 antibody, but it is not limited thereto.
- The pharmaceutical composition of the present invention may be in various types of preparation such as oral preparation or parenteral preparation. In case of producing a preparation, the preparation is made by using a diluent or a vehicle such as filler, bulking agent, binding agent, moisturizing agent, disintegrating agent, or surfactant that are commonly used for producing a preparation. Examples of the solid preparation for oral administration include a tablet, a pill, a powder, a granule, and a capsule. The solid preparation is produced by mixing at least one compound with one or more vehicles such as starch, calcium carbonate, sucrose, lactose, or gelatin. Furthermore, other than simple vehicles, a lubricating agent such as magnesium stearate or talc is also used. As for the liquid preparation for oral administration, a suspension, a solution preparation for internal use, an emulsion, a syrup preparation, or the like can be mentioned. Other than water or liquid paraffin commonly used as a simple diluent, various kinds of a vehicle such as moisturizing agent, sweetening agent, aromatic agent, or preservatives may be included.
- Examples of a preparation for parenteral administration include a sterilized aqueous solution, a non-soluble preparation, a suspension preparation, an emulsion preparation, a freeze-dried preparation, and a suppository preparation. As a water insoluble solvent or a suspending preparation, propylene glycol, polyethylene glycol, or vegetable oil such as olive oil, and injectable ester such as ethylolate can be used. As a base for a suppository preparation, witepsol, macrogol, tween 61, cacao fat, laurin fat, glycerol, gelatin, or the like can be used.
- The pharmaceutical composition of the present invention can be administered either orally or parenterally. In case of parenteral administration, it is preferable to choose external application on skin, or intraperitoneal, rectal, intravenous, muscular, subcutaneous, endometrium injection, or intracerebroventricular injection.
- The pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount. As described herein, the expression “pharmaceutically effective amount” means an amount sufficient for treating a disorder at reasonable benefit-risk ratio that can be applied for a medical treatment. The effective dose level may be determined based on a type or severeness of a disorder of a patient, activity of a pharmaceutical, sensitivity to a pharmaceutical, administration period, administration route, excretion ratio, time period for therapy, elements including a pharmaceutical used in combination, and other elements that are well known in the medical field. The composition of the present invention can be administered as a separate therapeutic agent, or it can be used in combination with other therapeutic agent. It can be administered in order or simultaneously with a conventional therapeutic agent. It can be also administered as single-dose or multi-dose. It is important to administer an amount which allows obtainment of the maximum effect with minimum dose while considering all of the aforementioned elements without having any side effect, and the dosage can be easily determined by a person skilled in the pertinent art.
- The dosage of the composition of the present invention may vary depending on body weight, age, sex, health state, diet of a patient, administration period, administration method, excretion rate, and severeness of disorder. However, the daily dosage is, in terms of the amount of Salvia plebeia extract, 0.01 to 2,000 mg/kg, preferably 30 to 500 mg/kg, and more preferably 50 to 300 mg/kg, and it can be administered 1 to 6 times per day. The pharmaceutical composition of the present invention may be used either singly, or in combination with other treatment methods including surgery, radiation therapy, hormone therapy, chemotherapy, antibody therapy, and a method of using biological response modifier.
- The present invention still further relates to an anti-cancer adjuvant comprising Salvia plebeia extract as an effective component.
- The anti-cancer adjuvant may comprise, in addition to the Salvia plebeia extract, one or more types of an effective component which exhibits similar or even identical effect to the extract. For clinical administration, the anti-cancer adjuvant may be administered either orally or parenterally. In case of parenteral administration, it may be administered via intraperitoneal injection, intrarectal injection, subcutaneous injection, intravenous injection, muscular injection, endometrium injection, intracerebroventricular injection, or intrathoracic injection, and it can be used in the form of a common pharmaceutical preparation.
- The anti-cancer adjuvant may be used either singly, or in combination with other methods including surgery, radiation therapy, hormone therapy, chemotherapy, and a method of using biological response modifier. The dosage of the anti-cancer adjuvant is about 0.0001 to 100 mg/kg, and preferably 0.001 to 10 mg/kg per day, and the administration can be made once a day, or several times a day with divided portion. The dosage is within a broad range depending on body weight, age, sex, health state, and diet of a patient, administration period and administration method, excretion rate, and severeness of disorder. For clinical administration, the anti-cancer adjuvant of the present invention may be administered parenterally in various preparation types, and in case of producing a preparation, the preparation can be made by using a diluent or a vehicle like a filling agent, a bulking agent, a binding agent, a wetting agent, a disintegrating agent, and a surfactant that are commonly used. Examples of a preparation for parenteral administration include a sterilized aqueous solution, a non-soluble preparation, a suspension preparation, an emulsion preparation, a freeze-dried preparation, and a suppository preparation. As a water insoluble solvent or a suspending preparation, propylene glycol, polyethylene glycol, or vegetable oil such as olive oil, and injectable ester such as ethylolate can be used. As a base for a suppository preparation, witepsol, macrogol, tween 61, cacao fat, laurin fat, glycerol, gelatin, or the like can be used.
- Hereinbelow, the present invention is explained in greater detail in view of the Examples. However, the following Examples are given only for specific explanation of the present invention and it would be evident to a person who has common knowledge in the pertinent art that the scope of the present invention is not limited by them.
- After drying 10 g of Salvia plebeia, 70% (v/v) ethanol (100 ml) was added thereto as a solvent. Reflux extraction of the mixture was carried out three times for 2 hours followed by concentration under reduced pressure to prepare Salvia plebeia extract.
- By utilizing competitive ELISA analysis, concentration-dependent binding of the ethanol extract of Salvia plebeia to PD-L1 was determined to examine the blockage of the interaction with PD-1.
- The competitive ELISA analysis was carried out according to the manufacturer's protocol using the PD-1/PD-L1 inhibitor screening kit. Recombinant human PD-L1 (1 μg/ml) dissolved in PBS was coated overnight on a 96-well plate. The 96-well plate was then washed with PBS containing 0.1% Tween (PBS-T) and blocked at room temperature for 1 hour with PBS containing 2% (w/v) BSA followed by washing again. After that, 0.5 μg/ml biotinylated hPD-1 (50 μl) was added to each well, and the plate was incubated for 2 hours at room temperature. After washing 3 times with PBS-T, 50 μl of streptavidin conjugated with HRP (0.2 μg/ml) were added to each well, and the plate was incubated for 1 hour. After the incubation, the plate was washed 3 times with 0.1% PBS-T, and relative chemical luminescence was measured by using SpectraMax L luminometer.
- As the result is shown in
FIG. 1 , it was found that PD-1/PD-L1 binding was inhibited in concentration dependent manner, and Salvia plebeia extract inhibits, with statistical significance, PD-1/PD-L1 binding in concentration dependent manner (FIG. 2 ). Based on this result, it was recognized that T cell activation is promoted via immune checkpoint inhibition, and thus the effect of inhibiting tumor proliferation against cancer cells is exhibited. - To determine the expression of hPD-L1 on surface of MC38 cells, flow cytometry was carried out. Specifically, to detect the surface expression of hPD-L1 (CD274) in MC38 cells, cells were suspended in phosphate-buffered physiological saline (PBS) with 0.2% bovine serum albumin. Then, the cells were treated on ice with ePC-conjugated anti-human PD-L1 antibody or APC-conjugated mouse IgG1 as an isotype control group followed by incubation for 30 minutes. Thereafter, the cells were washed with PBS and examined using CytoFLEX flow cytometer (Beckman, Brea, Calif., USA). The obtained data were analyzed using FlowJo Software version v10.
- As the result is shown in (A) of
FIG. 3 , it was found that normal expression of hPD-L1 is obtained. - Cell viability was measured by using CCK assay. On a 96 well plate, cells were spread in an amount of 1×104 cells/well and cultured overnight. After that, Salvia plebeia extract was added at each different concentration. CCK solution (10 μl) was then added and the plate was incubated for 2 hours at 37° C. Thereafter, color intensity was measured at 450 nm by using a microplate reader.
- As the result is shown in (B) of
FIG. 3 and (C) ofFIG. 3 , it was found that cell death is caused by a treatment with Salvia plebeia extract. - LDH activity and cancer cell death in Salvia plebeia extract (SPE) treatment group were determined after co-culture of human colon cancer cells (HCT116) and T cells. Specifically, colon cancer cells (HCT116) which have been treated with 10 ng/ml interferon gamma were spread on a 96 well plate in an amount of 5×104 cells/well and cultured for 18 hours to have adhesion on the plate bottom. After that, T cells having overexpressed PD-1 were aliquoted, in an amount of 1×105 cells/well, to the 96 well plate adhered with colon cancer cells, Salvia plebeia extract (12.5 or 25 μg/ml) was added, and co-culture was carried out for 72 hours. After that, the top part of the culture broth was aliquoted to a fresh 96 well plate and reagents for LDH assay were added to have a reaction. Once the reaction is over, a solution for terminating the reaction was added, and the absorbance at 540 nm was measured for each sample.
- As the result is shown in
FIG. 4 , it was found that, when co-culture is carried out following the treatment with Salvia plebeia extract, the LDH activity is enhanced to cause the death of cancer cells. - Cancer cell death according to co-culture with breast cancer cells (MCF-7) and T cells and also a treatment with Salvia plebeia extract (SPE) was determined. Co-culture with breast cancer cells (MCF-7) and T cells was carried out at a ratio of 1:2 or 1:5.
- Specifically, breast cancer cells (MCF-7) which have been treated with 10 ng/ml interferon gamma were spread on a 96 well plate in an amount of 5×104 cells/well and cultured for 18 hours to have adhesion on the plate bottom. After that, T cells having overexpressed PD-1 were aliquoted, in an amount of 1×105 cells/well for co-culture with a ratio of 1:2 or 2.5×105 cells/well for co-culture with a ratio of 1:5, to the 96 well plate adhered with breast cancer cells, Salvia plebeia extract (12.5, 25, 50 or 100 μg/ml) was added, and co-culture was carried out for 72 hours. After that, CCK solution (100 was added followed by incubation for 2 hours at 37° C. Absorbance at 450 nm was then measured for each sample using microplate.
- As the result is shown in
FIG. 5 , it was found that, when co-culture is carried out following the treatment with Salvia plebeia extract, the viability of breast cancer cells has decreased with statistical significance. - Cancer cell death according to co-culture with lung cancer cells (A549) and T cells and also a treatment with Salvia plebeia extract (SPE) was determined. Co-culture with lung cancer cells (A549) and T cells was carried out at a ratio of 1:2 or 1:5.
- Specifically, lung cancer cells (A549) which have been treated with 10 ng/ml interferon gamma were spread on a 96 well plate in an amount of 5×104 cells/well and cultured for 18 hours to have adhesion on the plate bottom. After that, T cells having overexpressed PD-1 were aliquoted, in an amount of 1×105 cells/well for co-culture with a ratio of 1:2 or 2.5×105 cells/well for co-culture with a ratio of 1:5, to the 96 well plate adhered with lung cancer cells, Salvia plebeia extract (12.5, 25, 50 or 100 μg/ml) was added, and co-culture was carried out for 72 hours. After that, CCK solution (10 μl) was added followed by incubation for 2 hours at 37° C. Absorbance at 450 nm was then measured for each sample using microplate.
- As the result is shown in
FIG. 6 , it was found that, when co-culture is carried out following the treatment with Salvia plebeia extract, the viability of lung cancer cells has decreased with statistical significance. - A mouse (C57BL/6J) in which mPD-1 has been removed and replaced by hPD-1 was used for the test, i.e., six animals for each group. MC38 cells (mouse colon cancer cells) obtained by removing mouse PD-L1 (mPD-L1) and replacing it with human PD-1 (hPD-L1) were injected to the animal. Starting from the 14th day after the injection, aPD-1 (positive control) or Salvia plebeia extract (100 or 300 mg/kg) was administered with a time interval shown in
FIG. 7 . Body weight of the animal and tumor size were then measured. - As the result is shown in
FIG. 7 , it was found that the tumor size has been reduced with statistical significance in the Salvia plebeia extract administration group of the present invention and the positive control group when compared to the group induced to have cancer (i.e., vehicle), while there is no clear change in the mouse body weight.
Claims (13)
1-12. (canceled)
13. A method for immune checkpoint inhibition, the method comprising administering a composition comprising a Salvia plebeia extract as an effective component to a subject in need thereof.
14. The method of claim 13 , wherein the Salvia plebeia extract is produced by using an extraction solvent selected from the group consisting of water, a C1-C4 lower alcohol, and a mixture thereof.
15. The method of claim 13 , wherein the Salvia plebeia extract has PD-L1 or PD-1 as a target.
16. The method of claim 15 , wherein the PD-L1 is found on cancer cell which is a cell originating from any cancer selected from colon cancer, breast cancer, lung cancer, melanoma, liver cancer, stomach cancer, colorectal cancer, skin cancer, bladder cancer, prostate cancer, ovary cancer, cervical cancer, thyroid cancer, kidney cancer, fibrosarcoma, and leukemia.
17. A method for treating a disorder related to immune checkpoint inhibition, the method comprising administering a composition comprising a Salvia plebeia extract as an effective component to a subject in need thereof.
18. The method of claim 17 , wherein the disorder related to immune checkpoint inhibition is at least one of cancer, infection, sepsis, and immune aging.
19. The method of claim 18 , wherein the disorder related to immune checkpoint inhibition is the cancer selected from the group consisting of colon cancer, breast cancer, lung cancer, melanoma, liver cancer, stomach cancer, colorectal cancer, skin cancer, bladder cancer, prostate cancer, ovary cancer, cervical cancer, thyroid cancer, kidney cancer, fibrosarcoma, leukemia, and a combination thereof.
20. A method for treating a cancer, the method comprising administering a composition comprising an anti-cancer active agent and a Salvia plebeia extract as an effective component to a subject in need thereof.
21. The method of claim 20 , wherein the anti-cancer active agent comprises at least one of an anti-cancer agent and an immune checkpoint inhibitor.
22. The method of claim 21 , wherein the anti-cancer active agent comprises the anti-cancer agent selected from the group consisting of actinomycin D, bleomycin sulfate, daunomycin, daunorubicin, doxorubicin, epirubicin, idarubicin, mitomycin, mitomycin-C, mithramycin, irinotecan, camptothecin, novobiocin, epirubicin, dactinomycin, amsacrine, teniposide, etoposide, cisplatin, carboplatin, oxaliplatin, paclitaxel, docetaxel, gefitinib, erlotinib, afatinib, and a combination thereof.
23. The method of claim 21 , wherein the anti-cancer active agent comprises the immune checkpoint inhibitor selected from the group consisting of anti PD-L1 antibody, anti PD-1 antibody, anti CD-80 antibody, anti CTLA-4 antibody, and a combination thereof.
24. The method of claim 20 , wherein the composition includes the anti-cancer active agent and an anti-cancer adjuvant comprising the Salvia plebeia extract.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20190137681 | 2019-10-31 | ||
KR10-2019-0137681 | 2019-10-31 | ||
PCT/KR2020/013292 WO2021085872A1 (en) | 2019-10-31 | 2020-09-29 | Composition, comprising salvia plebeia r. br. extract as active ingredient, for inhibiting tumor growth |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220362322A1 true US20220362322A1 (en) | 2022-11-17 |
Family
ID=75715310
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/773,243 Pending US20220362322A1 (en) | 2019-10-31 | 2020-09-29 | Composition for inhibiting tumor proliferation comprising salvia plebeia extract as effective component |
Country Status (3)
Country | Link |
---|---|
US (1) | US20220362322A1 (en) |
KR (1) | KR102640481B1 (en) |
WO (1) | WO2021085872A1 (en) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101374536B1 (en) * | 2011-06-10 | 2014-03-14 | 박혜림 | Composition for reinforced immunity using Gombo-Baechu |
WO2013176471A1 (en) * | 2012-05-21 | 2013-11-28 | 한국생명공학연구원 | Pharmaceutical composition for preventing or treating stat3-mediated disease, comprising salvia plebeia r. br. extract or fraction thereof as active ingredient |
KR20150127849A (en) * | 2012-07-12 | 2015-11-18 | 주식회사 웰파이토 | Healthy food composition having anti-oxidative activity |
KR101817055B1 (en) * | 2013-07-10 | 2018-01-11 | 주식회사 웰파이토 | Food composition having anti-obesity, anti-cancer, anti-oxidative and immunity enhancing activities |
KR101705547B1 (en) * | 2013-07-12 | 2017-02-13 | 주식회사 웰파이토 | Composition for antioxidant or anticancer or antidiabete or antimicrobial containing balloon flower extract |
KR101794567B1 (en) * | 2015-06-11 | 2017-11-07 | 주식회사 케이티앤지 | The composition comprising the specific extract or the purified fraction isolated from Salvia pleia R. Br. as an active ingredient for preventing or treating respiratory inflammatory disease |
-
2020
- 2020-09-29 KR KR1020200126483A patent/KR102640481B1/en active IP Right Grant
- 2020-09-29 WO PCT/KR2020/013292 patent/WO2021085872A1/en active Application Filing
- 2020-09-29 US US17/773,243 patent/US20220362322A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20210052227A (en) | 2021-05-10 |
KR102640481B1 (en) | 2024-02-26 |
WO2021085872A1 (en) | 2021-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101797813B1 (en) | Compositions for preventing or treating bladder cancer comprising citrus fermentd broth with Kombucha as an active ingredient | |
JP5688467B2 (en) | A composition for preventing or treating dementia (dementia), containing a ume extract | |
KR20060108225A (en) | A process for preparing novel processed ginseng to obtain increased amount of ginsenoside rg5 and the composition comprising the same | |
US20220362322A1 (en) | Composition for inhibiting tumor proliferation comprising salvia plebeia extract as effective component | |
US9737583B2 (en) | Composition for prevention or treatment of acute renal failure including herbal extract or fraction thereof as active ingredient | |
KR102556464B1 (en) | Composition for inhibiting proliferation of tumor comprising Oenothera Radix extract as effective component | |
KR102348782B1 (en) | Composition for preventing or treating renal disease comprising Zizyphus jujuba MILL extract | |
KR101446784B1 (en) | Pharmaceutical composition for anticancer comprising extract of sea cucumber or its fraction as effective component | |
KR102043454B1 (en) | Composition for preventing, ameliorating or treating anti-cancer drug-resistant lung cancer comprising gliotoxin as effective component | |
KR101715996B1 (en) | Composition for antidiabetic activity comprising dichloromethane or ethyl acetate fraction of Hizikia fusiformis extract as effective component | |
JP5097356B2 (en) | New anticancer drug | |
WO2023027301A1 (en) | Composition comprising rubus coreanus extract as active ingredient for inhibiting tumor growth | |
KR101575702B1 (en) | Pharmaceutical compositions containing extract of Phellinus baumii or fraction thereof of wound-healing or skin activation | |
KR102558650B1 (en) | Composition for preventing, ameliorating or treating prostate cancer comprising Hippocampus abdominalis and herbal medicine mixed extract as effective component | |
KR20220151074A (en) | Composition for inhibiting proliferation of tumor comprising Sanguisorba officinalis extract as effective component | |
KR102230537B1 (en) | Composition for preventing, improving or treating cancer comprising extract of Euryale ferox Salisb as effective component | |
WO2023249075A1 (en) | Prophylactic or therapeutic agent for non-alcoholic steatohepatitis-derived hepatocarcinoma | |
KR102096345B1 (en) | Composition for preventing, improving or treating vasculitis comprising Curcuma zedoaria extract as effective component | |
KR20230056882A (en) | Composition for preventing, improving or treating cancer comprising extract of Ribes fasciculatum var. chinense or fraction thereof as effective component | |
JP2022035343A (en) | Formulation for promoting apoptosis of cancer cells and/or inhibiting growth of cancer cells | |
KR20240000686A (en) | Composition for anticancer comprising Bojungikki-tang and immune checkpoint inhibitor as effective component | |
KR20210112534A (en) | Skin cancer prevention or skin cancer metastasis inhibiting composition comprising Inula japonica Thunberg extract | |
KR101349747B1 (en) | A composition comprising extracts and fractions of Wercklea insignis for prevention and treatment of inflammatory diseases or asthma | |
JP2024057701A (en) | Composition for inhibiting formation of spots or improving spots, comprising an IL-6 receptor inhibitor | |
KR20150061115A (en) | Pharmaceutical composition comprising maysin for the prevention and treatment of obesity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |